Friday, 6 November 2026European Markets

IDEX BIOMETRICS Stock Bullish Momentum With A 9.44% Jump Today

Loading stream...

(VIANEWS) - The Market ended the session with IDEX BIOMETRICS (IDEX.OL) jumping 9.44% to kr1.58 on Monday while Oslo Børs Benchmark Index_GI rose 0.14% to kr1,393.52.

IDEX BIOMETRICS's last close was kr1.45, 62.66% under its 52-week high of kr3.88.

About IDEX BIOMETRICS

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless smart cards, that includes financial payment and access control cards, as well as card-based devices for the storage of digital currencies. It primarily serves smart card manufacturers and similar solution integrators. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-1.06.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -223.25%.

Volatility

IDEX BIOMETRICS's last week, last month's, and last quarter's current intraday variation average was a negative 1.81%, a negative 0.72%, and a positive 4.34%.

IDEX BIOMETRICS's highest amplitude of average volatility was 1.81% (last week), 1.94% (last month), and 4.34% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 70%, now sitting on 3.27M for the twelve trailing months.

Volume

Today's last reported volume for IDEX BIOMETRICS is 6949240 which is 146.34% above its average volume of 2820930.

Moving Average

IDEX BIOMETRICS's value is way under its 50-day moving average of kr1.85 and way under its 200-day moving average of kr2.21.

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com